NCT00326469

Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours

Phase II, Open, Single Group, Multicentre Study to Evaluate the Efficacy and Safety of Lanreotide Autogel Administered Every 4 Weeks by Deep Subcutaneous Injection in the Tumour's Growth Stabilization of Patients With Progressive Neuroendocrine Tumours Who Are Not Eligible to be Treated With Either Surgery or Chemotherapy

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Ipsen · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate, in patients with progressive neuroendocrine tumours who are not eligible to be treated with either surgery or chemotherapy at the moment of study inclusion, the efficacy of lanreotide Autogel in tumour growth stabilization.

Conditions

• Neuroendocrine Tumours

Interventions

Type	Name	Description
DRUG	lanreotide (Autogel formulation)	120mg administered via deep subcutaneous injection every 28 days for up to 24 months or until disease progression.

Timeline

• Start date: 2006-05-01
• Primary completion: 2009-11-01
• Completion: 2009-11-01
• First posted: 2006-05-16
• Last updated: 2020-11-05

Locations

27 sites across 1 country: Spain